Clinical Trial Search Results
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advance Solid Refractory/Resistant Malignancies
You are being invited to take part voluntarily in this research study because you have a solid tumor that hasn’t responded to previous treatment or has spread to other parts of your body (metastatic), including ovarian, cervica ...
A Phase 1b Open-label Study Evaluating the Safety and Pharmacokinetics of Subcutaneous AMG 701 for the Treatment of Relapsed or Refractory Multiple Myeloma (ProxiMMity-1)
Participants who have have relapsed (returning) and refractory (stopped responding to treatment) multiple myeloma (RRMM) will be invited to take part in this study. This study is being done to learn more about the drug AMG 701 ...
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects with Moderate COVID-19
You are being asked to take part in a clinical research study of an oral drug called AT-527 (a direct-acting antiviral drug). AT-527 is an investigational drug, which means it has not been approved for the treatment of any dise ...
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
The overall goal of this study is to find out if a reduced dose of radiation to the whole brain and spine and less chemotherapy can be given to children and young adults with WNT subtype medulloblastoma without increasing the r ...
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
The overall goal of this study are to: Part 1 - Find the best dose of ruxolitinib to use with standard chemotherapy in children, adolescents, and young adults with HR B-ALL; Part 2 - Find out if the investigational drug ruxolit ...
A Phase 2 trial of Nirogacestat in Patients with Recurrent Ovarian Granulosa
Cell Tumors
Cell Tumors
You are being asked to take part in a clinical research study because you have a rare type of ovarian cancer known as ovarian granulosa cell tumor (also known as sex cord-stromal tumor). A person who takes part in a research st ...
A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks.
You, or you and the individual you care for, are being asked to take part in a research study because you have seizures associated with developmental and epileptic encephalopathy (DEE) and you have completed study LP352-201. L ...
A Phase 2/3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Participants with Moderately to Severely Active Crohn’s Disease with an Inadequate Response to Conventional Therapy
The purpose of this study is to see whether ozanimod (RPC1063, also referred to as the ‘study drug’ or ‘study treatment’) is safe and effective for the possible treatment of Crohn’s Disease (CD) in a pediatric population. To do ...
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
This study looks at how well a drug called selumetinib works when given to children and young adults with LGG. The study doctors want to see if selumetinib works as well as CV for getting rid of or shrinking LGGs and stopping t ...